[HTML][HTML] EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
B Hellmich, B Sanchez-Alamo, JH Schirmer… - Annals of the …, 2024 - ard.bmj.com
Background Since the publication of the EULAR recommendations for the management of
antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several …
antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several …
Rituximab induction and maintenance in ANCA-associated vasculitis: state of the art and future perspectives
E Treppo, M Binutti, R Agarinis, S De Vita… - Journal of Clinical …, 2021 - mdpi.com
Antineutrophil cytoplasmatic antibody (ANCA)-associated vasculitis (AAV) is a group of rare
autoimmune diseases characterized by inflammation of the vascular wall. The pathogenesis …
autoimmune diseases characterized by inflammation of the vascular wall. The pathogenesis …
[PDF][PDF] Updates in ANCA-associated vasculitis
Antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) are small-vessel
vasculitides that include granulomatosis with polyangiitis (formerly Wegener's …
vasculitides that include granulomatosis with polyangiitis (formerly Wegener's …
Comparison of outcomes using the rituximab originator MabThera with the biosimilar truxima in patients with ANCA-associated vasculitis
M Antonelou, A Abro, R Heath, A Iacovou… - Scandinavian Journal …, 2022 - Taylor & Francis
Objectives The use of rituximab (MabThera®), an anti-CD20 monoclonal antibody, is the
most significant development in the management of anti-neutrophil cytoplasm antibody …
most significant development in the management of anti-neutrophil cytoplasm antibody …
A developer's perspective on clinical evidence and benefits for rituximab biosimilar uptake, with a focus on CT-P10
D Choi, S Lee, S Kim, S Yoon - Clinical Drug Investigation, 2022 - Springer
To date, four rituximab biosimilars have received regulatory approval from the European
Medicines Agency and/or US Food and Drug Administration. CT-P10 was the first rituximab …
Medicines Agency and/or US Food and Drug Administration. CT-P10 was the first rituximab …
Update on maintenance therapies for ANCA-Associated Vasculitis
C Pagnoux, A Fifi-Mah - Current Treatment Options in Rheumatology, 2021 - Springer
Purpose of review Over the past decades, maintenance therapy in anti-neutrophil cytoplasm
antibody (ANCA)-associated vasculitis (AAV) has greatly evolved, in a smooth step-wise …
antibody (ANCA)-associated vasculitis (AAV) has greatly evolved, in a smooth step-wise …
Тактика ведения тяжелого АНЦА-ассоциированного гломерулонефрита: сравнение международных рекомендаций и обзор литературы
АС Зыкова, ЕВ Захарова - Нефрология и диализ, 2024 - journal.nephro.ru
Аннотация Тяжелое поражение почек при АНЦА-ассоциированном васкулите остается
серьезной проблемой для практикующего врача ввиду сложности определения самого …
серьезной проблемой для практикующего врача ввиду сложности определения самого …
POS0252 IMPACT OF ANCA-ASSOCIATED VASCULITIS ON CLINICAL OUTCOMES AND RESOURCE UTILIZATION IN ELECTIVE PCI
K Mathias, L Mathias, A Mantha, D Arkfeld - 2021 - ard.bmj.com
Background: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitides (AV) can
increase risk of atherosclerosis. 1 Patients with autoimmune disease have increased rates of …
increase risk of atherosclerosis. 1 Patients with autoimmune disease have increased rates of …
POS0253 RITUXIMAB-BIOSIMILAR FOR ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES-ASSOCIATED VASCULITIS: EXPERIENCE OF A SINGLE ITALIAN …
S Sartorelli, A Cariddi, L Moroni, E Baldissera… - 2021 - ard.bmj.com
Background: Rituximab (RTX), an anti-CD20 monoclonal antibody, represents a valuable
treatment for anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) …
treatment for anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) …
POS0254 EFFICACY OF APREMILAST IN THE TREATMENT OF ORAL ULCERS OF BEHÇET'S SYNDROME: RESULTS FROM THE EUROPEAN SUBGROUP OF …
Background: Behçet's syndrome, a chronic, multi-system variable vessel vasculitis, is often
characterized by painful oral ulcers (OU) affecting quality of life (QoL). Apremilast (APR), an …
characterized by painful oral ulcers (OU) affecting quality of life (QoL). Apremilast (APR), an …